HRP20171694T1 - Novi pripravci i postupci - Google Patents

Novi pripravci i postupci Download PDF

Info

Publication number
HRP20171694T1
HRP20171694T1 HRP20171694TT HRP20171694T HRP20171694T1 HR P20171694 T1 HRP20171694 T1 HR P20171694T1 HR P20171694T T HRP20171694T T HR P20171694TT HR P20171694 T HRP20171694 T HR P20171694T HR P20171694 T1 HRP20171694 T1 HR P20171694T1
Authority
HR
Croatia
Prior art keywords
intended
seq
polypeptide
rv1753c
polynucleotide
Prior art date
Application number
HRP20171694TT
Other languages
English (en)
Croatian (hr)
Inventor
James Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals S.A.
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A., Glaxo Group Limited filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20171694T1 publication Critical patent/HRP20171694T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
HRP20171694TT 2008-07-25 2009-07-24 Novi pripravci i postupci HRP20171694T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8369208P 2008-07-25 2008-07-25
PCT/EP2009/059586 WO2010010180A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods
EP09781058.4A EP2315597B1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (1)

Publication Number Publication Date
HRP20171694T1 true HRP20171694T1 (hr) 2017-12-15

Family

ID=41172233

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171694TT HRP20171694T1 (hr) 2008-07-25 2009-07-24 Novi pripravci i postupci

Country Status (24)

Country Link
US (2) US9315556B2 (https=)
EP (1) EP2315597B1 (https=)
JP (1) JP5824360B2 (https=)
KR (2) KR20110060891A (https=)
CN (2) CN102164612B (https=)
AU (1) AU2009273133B2 (https=)
BR (1) BRPI0916705A2 (https=)
CA (1) CA2731549C (https=)
CO (1) CO6400198A2 (https=)
CY (1) CY1119737T1 (https=)
EA (1) EA022203B1 (https=)
ES (1) ES2647321T3 (https=)
HR (1) HRP20171694T1 (https=)
HU (1) HUE037121T2 (https=)
IL (1) IL210588A0 (https=)
LT (1) LT2315597T (https=)
MX (1) MX2011000981A (https=)
NO (1) NO2315597T3 (https=)
PL (1) PL2315597T3 (https=)
PT (1) PT2315597T (https=)
SG (1) SG10201505149WA (https=)
SI (1) SI2315597T1 (https=)
UA (1) UA107180C2 (https=)
WO (1) WO2010010180A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
WO2020214961A1 (en) * 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Methods of treating tuberculosis
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016146A (en) * 1974-12-10 1977-04-05 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies, and use
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
PL202844B1 (pl) 1998-04-07 2009-07-31 Corixa Corp Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
WO2001019993A2 (en) 1999-09-17 2001-03-22 University Of Maryland, Baltimore Virulence genes of m. marinum and m. tuberculosis
EP1229931A4 (en) 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
US7424370B2 (en) * 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
DK2457926T3 (da) * 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
AU2009273130B2 (en) 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
MX2011011186A (es) 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.

Also Published As

Publication number Publication date
CN102164612A (zh) 2011-08-24
UA107180C2 (uk) 2014-12-10
US20160184420A1 (en) 2016-06-30
JP5824360B2 (ja) 2015-11-25
KR20110060891A (ko) 2011-06-08
BRPI0916705A2 (pt) 2015-11-10
CO6400198A2 (es) 2012-03-15
KR20160013262A (ko) 2016-02-03
CN102164612B (zh) 2018-01-16
CN108059660A (zh) 2018-05-22
US9750794B2 (en) 2017-09-05
AU2009273133B2 (en) 2014-06-05
PL2315597T3 (pl) 2018-01-31
MX2011000981A (es) 2011-03-02
ES2647321T3 (es) 2017-12-20
WO2010010180A1 (en) 2010-01-28
CA2731549C (en) 2018-07-17
US9315556B2 (en) 2016-04-19
HUE037121T2 (hu) 2018-08-28
CY1119737T1 (el) 2018-06-27
NO2315597T3 (https=) 2018-01-20
EP2315597A1 (en) 2011-05-04
IL210588A0 (en) 2011-03-31
PT2315597T (pt) 2017-11-20
EA022203B1 (ru) 2015-11-30
JP2011528897A (ja) 2011-12-01
LT2315597T (lt) 2018-02-12
SI2315597T1 (sl) 2017-12-29
US20110223200A1 (en) 2011-09-15
SG10201505149WA (en) 2015-07-30
CA2731549A1 (en) 2010-01-28
EA201100071A1 (ru) 2011-10-31
AU2009273133A1 (en) 2010-01-28
EP2315597B1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
HRP20171694T1 (hr) Novi pripravci i postupci
RU2016146198A (ru) Терапевтические dll4-связывающие белки
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
JP2013172734A5 (https=)
IL278014B1 (en) Anti-myostatin antibodies, polypeptides containing variable fc regions and methods of use
EA201270517A1 (ru) Микобактериальные вакцины
DK2707393T3 (da) Fusionsproteiner og kombinationsvacciner omfattende haemoph-ilus influenzae-protein e og pilin a
NZ604818A (en) Variants of activin iib receptor polypeptides and uses thereof
JP2011528896A5 (https=)
HK1200842A1 (en) Proteins with improved half-life and other properties
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
MX2012004090A (es) Polipeptidos para unirse al "receptor para productos terminales de glicacion avanzados" asi como composiciones y metodos que involucran los mismos.
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EP2292647A3 (en) Small Streptococcus pyogenes antigens and their use
EP2289544A3 (en) Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
WO2008084072A3 (en) Protective proteins of s. agalactiae, combinations thereof and methods of using the same
WO2011056954A8 (en) Haemophilus parasuis polypeptides and methods of use
MX2010005816A (es) Epítopos de péptido de stat3.
JP2013542942A5 (https=)
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
WO2007010080A3 (es) Nuevos dendrímeros carbosilanos, su preparación y sus usos